Cambridge Cognition Holdings PLC Wearable technology demonstrates high compliance
28 November 2017 - 6:01PM
RNS Non-Regulatory
TIDMCOG
Cambridge Cognition Holdings PLC
28 November 2017
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Wearable technology demonstrates high compliance
The digital neuroscience company Cambridge Cognition Holdings
plc, (AIM: COG, 'the Company'), which develops and markets software
products to improve brain health, has released positive results
from a pilot study to evaluate cognition and mood using wearable
technology in patients with major depressive disorder (MDD) at the
2017 International CNS Summit in Boca Raton, FL.
The study was sponsored by Takeda Pharmaceuticals and used
Cognition Kit(TM) technology, developed in a joint venture between
Cambridge Cognition and Ctrl Group to measure mood and cognition in
real world settings.
Collecting data in normal, day-to-day circumstances is a growing
trend in the healthcare industry. Pharmaceutical companies now aim
to demonstrate evidence of successful real world outcomes to
differentiate their products in a competitive market while also
satisfying the demands of payers and patients.
Real world evidence can help improve health outcomes for
patients, reduce medical costs and demonstrate the
cost-effectiveness of a treatment. However, conducting studies
outside of a clinical setting and gaining compliance from patients
when unsupervised has to date been challenging.
In the reported study, thirty participants aged 18-65 with a
clinical diagnosis of mild to moderate depression who had been
prescribed antidepressants took part over a 6-week period, being
assessed daily at regular intervals on the Apple Watch(R) .
The researchers found that patients were highly compliant with
the wearable Cognition Kit technology on a daily basis to evaluate
their mood (95 percent compliant) and cognitive health (96 percent
compliant).
The data collected with Cognition Kit shows how wearable
technology can be used to collect real world evidence reliably even
in challenging patient groups and how it may also aid communication
between patients and clinicians, ensuring symptoms are detected
early.
Dr. Francesca Cormack, Director of Research and Innovation, at
Cambridge Cognition said: "We are delighted by the study results.
These findings demonstrate that high frequency, near-patient
testing using Cognition Kit software on wearable devices is
accurate and well-tolerated by patients with excellent levels of
compliance. This is of huge significance, demonstrating a feasible
technology platform for enabling the pharmaceutical industry to
collect real world evidence."
Nicole Mowad-Nassar, Vice President, External Partnerships, at
Takeda Pharmaceuticals U.S.A. said: "This initiative is an
excellent example of the work being done at Takeda to build a body
of evidence for new ways of measuring outcomes in mental health.
Technology like Cognition Kit allows us to create real time
objective measurements for assessing effects in depression that
could transform patient care by increasing our ability to estimate
clinical conditions and support earlier engagement between the
patient and clinician. We are encouraged by the study results and
look forward to learning more about the intersection of technology
and healthcare."
Enquiries
Cambridge Cognition Holdings PLC
Steven Powell, Chief Executive Tel: 01223 810
Officer 700
Noah Konig, Director of Marketing press@camcog.com
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220
Geoff Nash / Simon Hicks 0500
Alice Lane (Corporate Finance)
(Corporate Broking)
Dowgate Capital Stockbrokers Limited Tel: 020 3903
(Joint Broker) 7715
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR Tel: 020 3053
and IR) 8671
Tim Metcalfe / Graham Herring /
Miles Nolan
About Cambridge Cognition
Cambridge Cognition is a neuroscience digital health company
developing products to better understand, detect and treat brain
health conditions. The company's cognitive technologies accelerate
research and development of new treatments, enhance understanding
of the brain and accurately measure cognitive health in patients
worldwide.
For further information visit www.cambridgecognition.com
About Cognition Kit
Cognition Kit is a joint venture between Cambridge Cognition and
Ctrl Group formed in 2016 to develop digital health tools on mobile
and wearable devices. Cognition Kit software takes research out of
the lab and into daily life, enabling doctors, scientists and the
public to better understand and manage day-to-day brain health.
For further information visit www.cognitionkit.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAZMMZMLNNGNZG
(END) Dow Jones Newswires
November 28, 2017 02:01 ET (07:01 GMT)
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Apr 2024 to May 2024
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From May 2023 to May 2024